Problem

Play Health addresses the menopause-care gap: menopause is common and under-addressed, yet only 39% of providers report feeling very confident managing menopause symptoms and just 31% of medical residents report receiving menopause curriculum. About 1.3 million U.S. women enter menopause each year, and most experience symptoms. The pain is both clinical and operational: patient data alone does not translate into a care decision without clinical context and evidence, while high-volume practices have limited time to reconstruct histories, review charts, and document visits. The broader economic burden is material; one cited Mayo Clinic estimate puts lost work time associated with menopause symptoms at $1.8 billion annually.

The killer use case is the menopause visit between periods of symptom tracking. A patient arrives with weeks or months of symptom, medication, lifestyle, and possibly wearable data, but the clinician needs a fast way to identify what is most important, understand what changed, and select an evidence-based intervention rather than rely on memory or trial and error.

Product / Service

Play Health combines a free patient-facing PeriMenopause App with Play Health Nav, a provider-facing clinical copilot. Patients can track symptom severity, cycle patterns, medications, and other information on iOS, Android, or the web, and can connect data from Oura, Apple Health, Google Health, Whoop, and Garmin. Patients may use the app independently or share their tracked information with a participating provider.

Nav brings that longitudinal record into the clinical workflow, ranking symptoms by impact, surfacing evidence-based interventions and FDA-approved therapies to consider, showing response to prior medications or lifestyle changes, and producing an editable, chart-ready visit summary. The product is designed to reduce administrative burden and make care more personalized while keeping clinical judgment with the licensed provider; its infrastructure is described as HIPAA-compliant and its guidance is grounded in sources including the FDA, ACOG, and The Menopause Society.

Market

Play Health operates in digital women's health, specifically provider-facing menopause and perimenopause clinical decision support. Its positioning is distinct from a standalone symptom tracker or a telehealth clinic: it connects patient-generated data to traditional-care workflows. The addressable need is substantial, with YC describing more than 30 million women in the U.S. as the relevant population. Adjacent menopause-care competitors include Midi Health and Alloy Health, which provide specialized telehealth services, while Crunchbase lists Hormona, EverlyWell, and Jayla Health as possible alternatives.

The company appears to be an early-stage, active startup rather than a scaled incumbent. Y Combinator lists it as founded in 2025, in the Fall 2025 batch, with a four-person team and active status; PitchBook reports $500,000 raised from investors including Y Combinator and Rebel Fund. The available evidence does not establish revenue, customer counts, or paid deployments, so traction is not quantitatively disclosed and the company cannot be classified definitively as pre-revenue from the available record.